Please login to the form below

Not currently logged in

Baraclude interim data issued by BMS

Bristol-Myers Squibb (BMS) has announced positive 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis

Bristol-Myers Squibb (BMS) has announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in which Baraclude demonstrated greater viral suppression compared to adefovir.

"This study represents an important first step in addressing an unmet medical need, as this is one of the first comparative studies to evaluate the safety and efficacy of antiviral therapy in this difficult-to-treat patient population," said Professor Hugo Cheinquer, ETV-048 study investigator and associate professor of gastroenterology and hepatology, Universidade Federal Do Rio Grande Do Sul, Brazil. "Chronic hepatitis B is a lifelong disease and these data suggest that treatment with Baraclude may offer chronic hepatitis B patients with decompensated cirrhosis a treatment option."

Decompensated cirrhosis is characterised by severe scarring of the liver caused by chronic liver inflammation, including inflammation associated with chronic hepatitis B infection. It is estimated that 15 to 25 per cent of chronic hepatitis B patients die from complications of liver disease. Currently, the median survival rate in decompensated patients is two to three years, with only 28 per cent of patients surviving for more than five years. The treatment of chronic hepatitis B patients with decompensated cirrhosis remains an area of unmet medical need, and these patients often require liver transplant.

2nd November 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...